Loading cancer entity…
Loading cancer entity…
Clinical trials
1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06468267 | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06509945 |
| Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL |
| unknown |
| N/A |
| 50 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Aug 1, 2024 |
| clinicaltrials |
| NCT06492629 | Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06434467 | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | unknown | Phase 3 | 83 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06433362 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 2 | 115 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06421571 | The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients(GR-CTCL_CL) | unknown | — | 40 | National and Kapodistrian University of AthensOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT05934864 | Different Molecular Subtypes of Peripheral T-cell Lymphoma, a Real-world Registry Study. (TRUST) | unknown | — | 1,000 | Ruijin HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06173999 | A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma | unknown | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT06406556 | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL(ENKTL) | unknown | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT04745234 | Mogamulizumab Q4week Dosing in Participants With R/R CTCL | unknown | Phase 2 | 34 | Kyowa Kirin, Inc.INDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT05075460 | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | unknown | Phase 3 | 107 | Peking Union Medical College HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04470947 | Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies(EXALT-2) | unknown | — | 150 | Medical University of ViennaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06224049 | Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T(GI-hNeoT-01) | unknown | Early Phase 1 | 6 | BGI, ChinaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05904522 | Histopathological Changes in Mycosis Fungoides | unknown | N/A | 10 | Bezmialem Vakif UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04582487 | Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL | unknown | N/A | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06224842 | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | unknown | Phase 1 / Phase 2 | 30 | Huijing WuOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT06083701 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study | unknown | Phase 1 / Phase 2 | 32 | Peking Union Medical College HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT04712864 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | unknown | Phase 1 | 50 | Legend Biotech USA IncINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05963347 | Go-CHOP as the Frontline Therapy for PTCL | unknown | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 1, 2023 | clinicaltrials |
| NCT05979792 | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | unknown | Early Phase 1 | 35 | Zhao WeiliOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05934045 | Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma(CIRComa) | unknown | — | 80 | University Hospital, ToulouseOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04554511 | Prognostic Nomogram of Extranodal NK/T-cell Lymphoma | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05907447 | A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types | unknown | — | 10,000 | Ruijin HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04480099 | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | Phase 2 | 96 | Ruijin HospitalOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05900089 | Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma | unknown | Phase 1 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05896813 | CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unknown | N/A | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05855460 | Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | unknown | — | 20 | Cairo UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05852028 | A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma | unknown | — | 250 | Ruijin HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05821192 | Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. | unknown | N/A | 34 | Ou Bai, MD/PHDOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT05772728 | Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL) | unknown | N/A | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 16, 2023 | clinicaltrials |
| NCT05526638 | Serum and Tissue Level of Interleukin-15 (IL-15) and IL-15 Receptor Alpha (IL-15Rα) in Mycosis Fungoides | unknown | N/A | 15 | Cairo UniversityOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05017337 | Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular Contracture(BASILICA) | unknown | — | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | unknown | Phase 1 / Phase 2 | 116 | Ruijin HospitalOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT04118868 | Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma. | unknown | Phase 1 | 10 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT05367856 | Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT05557903 | Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL | unknown | Phase 1 | 71 | Lanzhou Institute of Biological Products Co., LtdINDUSTRY | 1 | Sep 28, 2022 | clinicaltrials |
| NCT05495100 | A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma | unknown | Phase 2 | 45 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT03672084 | Allo-HSCT as First-line Consolidation in High-risk PTCL | unknown | — | 50 | Peking University People's HospitalOTHER | 1 | Aug 2, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT05466318 | ChiCGB vs BEAM in High-risk or R/R Lymphomas | unknown | Phase 3 | 306 | Sichuan UniversityOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05458180 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 1 | 18 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 14, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2024source: clinicaltrials